De novo functional discovery of peptide-MHC restricted CARs from recombinase-constructed large-diversity monoclonal T cell libraries., PMID:39651191
Revealing molecular and cellular heterogeneity in hypopharyngeal carcinogenesis through single-cell RNA and TCR/BCR sequencing., PMID:38720887
Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma., PMID:37866309
Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA)., PMID:37336938
Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients., PMID:36527482
Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity., PMID:35987136
Generalizable design parameters for soluble T cell receptor-based T cell engagers., PMID:35260435
The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients., PMID:34462402
MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation., PMID:33227008
Differential Expression of Cancer Testis Antigens on Lentigo Maligna and Lentigo Maligna Melanoma., PMID:32701706
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma., PMID:32114500
Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status., PMID:31407331
The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis., PMID:31093793
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials., PMID:30546947
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine., PMID:30219710
Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins., PMID:30186454
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic., PMID:30094070
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial., PMID:29908991
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature., PMID:29177094
Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab., PMID:28951518
An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide., PMID:28910565
The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions., PMID:28768706
Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg., PMID:28641561
Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Helicobacter pylori Infection in Gastric Cancer., PMID:28438869
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy., PMID:28146422
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting., PMID:27563655
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial., PMID:27132212
L-Rhamnose Enhances the Immunogenicity of Melanoma-Associated Antigen A3 for Stimulating Antitumor Immune Responses., PMID:26978574
Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination., PMID:26888315
Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells., PMID:26702740
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer., PMID:26309191
Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients., PMID:25944688
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention., PMID:25870800
Targeting the immune system to treat lung cancer: rationale and clinical experience., PMID:25827132
Immunotherapy in lung cancer., PMID:25806276
Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells., PMID:25704851
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)., PMID:25537079
Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment., PMID:25530039
Immunotherapy and lung cancer: current developments and novel targeted therapies., PMID:25496336
Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys., PMID:25219328
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer., PMID:25101620
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation., PMID:25078248
MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells., PMID:25031712
Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines., PMID:25030654
Absence of recognition of common melanocytic antigens by T cells isolated from the cerebrospinal fluid of a Vogt-Koyanagi-Harada patient., PMID:24991188
Update on vaccines for high-risk melanoma., PMID:24788575
Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer., PMID:24675493
MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine., PMID:24671426
[Advances in immunotherapies for non-small cell lung cancer]., PMID:24667269
Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy., PMID:24614036
For research use only. Not for human or drug use.
